Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part II. Evaluation in patients

Carrie B. Hruska, Amanda L. Weinmann, Christina M. Tello Skjerseth, Eric M. Wagenaar, Amy L. Conners, Cindy L. Tortorelli, Robert W. Maxwell, Deborah J. Rhodes, Michael K. O'Connor

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations


Purpose: Molecular breast imaging (MBI) has shown promise as an adjunct screening technique to mammography for women with dense breasts. The demonstration of reliable lesion detection with MBI performed at low administered doses of Tc-99 m sestamibi, comparable in effective radiation dose to screening mammography, is essential to adoption of MBI for screening. The concept of performing low-dose MBI with dual-head cadmium zinc telluride (CZT) gamma cameras has been investigated in phantoms in Part I. In this work, the objectives were to evaluate the impact of the count sensitivity improvement methods on image quality in patient MBI exams and to determine if adequate lesion detection could be achieved at reduced doses. Methods: Following the implementation of two count sensitivity improvement methods, registered collimation optimized for near-field imaging and energy acceptance window optimized for CZT, MBI exams were performed in the course of clinical care. Clinical image count density (counts/cm2) was compared between standard MBI [740 MBq (20 mCi) Tc-99 m sestamibi, standard collimation, standard energy window] and low-dose MBI [296 MBq (8 mCi) Tc-99 m sestamibi, optimized collimation, wide energy window] in a cohort of 50 patients who had both types of MBI exams performed. Lesion detection at low doses was evaluated in a separate cohort of 32 patients, in which low-dose MBI was performed following 296 MBq injection and acquired in dynamic mode, allowing the generation of images acquired for 2.5, 5, 7.5, and 10 min/breast view with proportionately reduced count densities. Diagnostic accuracy at each count density level was compared and kappa statistic was used to assess intrareader agreement between 10 min acquisitions and those at shorter acquisition durations. Results: In patient studies, low-dose MBI performed with 296 MBq Tc-99 m sestamibi and new optimal collimation/wide energy window resulted in an average relative gain in count density of 4.2 ± 1.3 compared to standard MBI performed with 740 MBq. Interpretation of low-dose 296 MBq images with count densities corresponding to acquisitions of 2.5, 5, 7.5, and 10 min/view and median lesion size of 1.4 cm resulted in similar diagnostic accuracy across count densities and substantial to near-perfect intrareader agreement between full 10 min-views and lower count density views. Conclusions: Review of patient studies showed that registered optimized collimation and wide energy window resulted in a substantial gain in count sensitivity as previously indicated by phantom results. This proof of concept work indicates that MBI performed at administered doses of 296 MBq Tc-99 m sestamibi with the applied count sensitivity improvements permits the detection of small breast lesions in patients. Findings suggest that further reductions in acquisition duration or administered dose may be achievable.

Original languageEnglish (US)
Pages (from-to)3476-3483
Number of pages8
JournalMedical Physics
Issue number6
StatePublished - Jun 2012
Externally publishedYes

Bibliographical note

Funding Information:
This research was supported by Mayo Clinic Foundation and grants from Komen for the Cure (BCTR0504394) and National Institutes of Health (R21R33 CA 128407). The Mayo Foundation and three authors of this work (C. B. Hruska, A. L. Weinmann, and M. K. O’Connor) obtain royalties from licensing arrangements between the Mayo Foundation and Gamma Medica-Ideas.


  • breast cancer
  • count sensitivity
  • gamma camera
  • molecular breast imaging
  • radiation risk


Dive into the research topics of 'Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part II. Evaluation in patients'. Together they form a unique fingerprint.

Cite this